8-K: Spero Therapeutics' Oral Antibiotic Trial Succeeds

Spero Therapeutics announced positive Phase 3 trial results for its oral antibiotic tebipenem HBr, extending its cash runway into 2028, while suspending its SPR720 program.

Summary

• The PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) patients was stopped early for efficacy following review by an independent data monitoring committee (IDMC).
• Spero, along with its development partner, GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in the second half of 2025.
• Existing cash and earned and non-contingent development milestone payments from GSK provide an anticipated runway to fund current operating expenses and capital expenditures into 2028.
• As of June 30, 2025, cash and cash equivalents were $31.2 million.
• The company reported a net loss of $1.7 million for the second quarter of 2025, a significant improvement from a net loss of $17.9 million for the second quarter of 2024.
• Total revenue for the second quarter of 2025 was $14.2 million, compared with $10.2 million for the same period in 2024, primarily due to collaboration revenue from GSK.
• Research and development expenses decreased to $10.7 million in Q2 2025 from $23.7 million in Q2 2024, primarily due to reduced clinical expense related to the PIVOT-PO trial.
• General and administrative expenses increased to $5.9 million in Q2 2025 from $5.5 million in Q2 2024, primarily due to increased personnel and professional service expense.
• The oral development program for SPR720 in NTM-PD was suspended in the fourth quarter of 2024 after a planned interim analysis of the Phase 2a trial demonstrated it did not meet its primary endpoint.
• Pursuant to the GSK License Agreement, the aggregate potential commercial milestone payments contingent upon first sales were adjusted from up to $150.0 million to up to $101.0 million after PIVOT-PO was stopped early for efficacy, as the maximum potential payment was contingent upon full enrollment of 2,637 patients.

Sentiment

Score: 8

Explanation: The early success of the pivotal Phase 3 trial for tebipenem HBr, a key pipeline asset, and the significant extension of the cash runway into 2028 are strong positive indicators. While the SPR720 program suspension is a negative, the overall financial improvement and progress on the lead candidate outweigh this, suggesting a very positive outlook for the company's primary focus.

Positives

• The Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint of non-inferiority and was stopped early for efficacy, indicating strong positive results.
• Existing cash and non-contingent milestone payments from GSK, including a final $23.8 million payment received in August 2025, provide an anticipated cash runway into 2028.
• Net loss significantly reduced to $1.7 million in Q2 2025 from $17.9 million in Q2 2024, demonstrating improved financial performance.
• Total revenue increased to $14.2 million in Q2 2025 from $10.2 million in Q2 2024, driven by increased collaboration revenue from GSK.
• Research and development expenses decreased due to the early completion of the PIVOT-PO trial, optimizing resource allocation.
• Tebipenem HBr has Qualified Infectious Disease Product (QIDP) designation and robust intellectual property protection through 2041.
• Tebipenem HBr has the potential to be the first oral carbapenem for cUTI, which could shorten hospital stays, improve patient outcomes, and reduce pressure on healthcare resources.

Negatives

• The SPR720 oral development program for NTM-PD was suspended in the fourth quarter of 2024, as the Phase 2a trial did not meet its primary endpoint.
• Aggregate potential commercial milestone payments from GSK for tebipenem HBr were adjusted down from up to $150.0 million to up to $101.0 million due to the early stopping of the PIVOT-PO trial, reducing the maximum potential payout.

Risks

• Whether tebipenem HBr will advance through the clinical development process, or at all, taking into account the effects of possible regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, clinical trial design, and clinical outcomes.
• Whether the results of such trials will warrant submission for approval from the FDA or equivalent foreign regulatory agencies.
• Whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval.
• Whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would delay approval and/or reduce the commercial prospects of tebipenem HBr.
• Whether a successful commercial launch can be achieved and market acceptance of tebipenem HBr can be established.
• Whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials.
• Reliance on third parties to manufacture, develop, and commercialize product candidates, if approved, including, in the case of tebipenem HBr, reliance on GSK pursuant to the exclusive GSK License Agreement to develop tebipenem HBr and GSK’s right thereunder to determine, in its sole discretion, whether to continue the PIVOT-PO trial or otherwise further develop tebipenem HBr.
• Need for additional funding.
• Ability to commercialize product candidates, if approved.
• Ability to retain key personnel.
• Leadership transitions.
• Whether cash resources will be sufficient to fund continuing operations for the periods and/or trials anticipated.
• Ability to obtain, maintain, and enforce intellectual property and other proprietary rights for product candidates.

Future Outlook

Spero Therapeutics, in collaboration with GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing for tebipenem HBr in the second half of 2025. If approved, tebipenem HBr is anticipated to be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTI), including pyelonephritis, potentially setting a new standard of care. The company is also determining next steps for the SPR720 program after its suspension.

Management Comments

• "During the second quarter, we announced that the tebipenem Phase 3 PIVOT-PO trial met its primary endpoint, marking a significant milestone for this program."
• "We look forward to working with GSK on next steps for this program which include completion of the Phase 3 data analysis and submission of the data package to the FDA."
• "There remains a critical unmet need for an oral carbapenem to treat complicated urinary tract infections, including pyelonephritis."
• "If approved, we believe tebipenem HBr could set a new standard of care for these infections, with the potential to shorten hospital stays, improve patient outcomes, and reduce pressure on healthcare resources."

Industry Context

The filing highlights a critical unmet need for effective oral treatments for complicated urinary tract infections (cUTI), including pyelonephritis, which currently lead to increased hospitalizations and healthcare costs. Tebipenem HBr, if approved, is positioned as a potential first-to-market oral carbapenem, offering a significant shift from current IV therapies for hospitalized patients. This could alleviate pressure on healthcare resources and improve patient convenience, addressing a large addressable patient population facing resistance and lack of effective oral options.

Comparison to Industry Standards

• Tebipenem HBr is positioned as potentially the first oral carbapenem for cUTI, differentiating it from existing IV therapies and other oral candidates like Iterum's Sulopenem etzadroxil (Orlynvah) and Utility's Pivmecillinam (Pivya), which are approved for uncomplicated UTIs.
• Earlier-stage oral candidates for cUTI include VenatoRx's Ceftibuten-ledaborbactam etzadroxil and Shionogi/Qpex's Ceftibuten-xeruborbactam oral prodrug, both in Phase 1.
• GSK's Gepotidacin is another oral candidate, approved in March 2025, but it targets uncomplicated UTIs, whereas Tebipenem HBr targets the more severe cUTI indication.
• The PIVOT-PO trial's success in meeting non-inferiority against intravenous imipenem-cilastatin sets a high bar, as imipenem-cilastatin is a standard IV carbapenem for severe infections.
• The extensive clinical experience with tebipenem pivoxil in Japan (approved since 2009 for pediatric pneumonia, otitis media, sinusitis, with over 4 million patients dosed) provides a strong safety and efficacy profile, which is a significant advantage compared to novel compounds without such a history.

Management Changes

Related Party Transactions

• Collaboration revenue from GSK, a development partner, contributed significantly to total revenue.
• Receipt of earned and non-contingent development milestone payments from GSK, including a final payment of $23.8 million received in August 2025.
• Adjustment of aggregate potential commercial milestone payments from GSK from up to $150.0 million to up to $101.0 million due to the early stopping of the PIVOT-PO trial.

Stakeholder Impact

• Shareholders: Positive impact due to successful Phase 3 trial, extended cash runway, reduced net loss, and potential for future regulatory and commercial milestones. Negative impact from SPR720 program suspension and reduced potential commercial milestones.
• Patients (cUTI): Potential for a new, effective oral treatment option (tebipenem HBr) that could shorten hospital stays and improve outcomes.
• Healthcare Providers: Potential for a new standard of care for cUTI, offering an oral alternative to IV therapy, potentially reducing pressure on healthcare resources.
• Employees: Stability provided by extended cash runway, but uncertainty for those involved in the suspended SPR720 program.
• GSK: Continued partnership and progress towards a potential new commercial product.

Next Steps

• Completion of Phase 3 data analysis for tebipenem HBr.
• Submission of tebipenem HBr data package to the FDA in 2H 2025.
• Submission of full PIVOT-PO results for presentation at an upcoming scientific meeting and for publication in a peer-reviewed journal.
• Determining next steps for the SPR720 program.
• Spero management to host a conference call and live audio webcast on August 12, 2025, to discuss the second quarter financial results and provide a business update.

Key Dates

Recommendation

The early and successful completion of the pivotal Phase 3 PIVOT-PO trial for tebipenem HBr, demonstrating non-inferiority against an IV standard of care, is a significant de-risking event for Spero's lead asset. This, coupled with the substantial extension of the cash runway into 2028 due to collaboration payments, provides strong financial stability and reduces immediate dilution risk. While the SPR720 program suspension is a setback, the focus on the highly promising tebipenem HBr, which addresses a critical unmet medical need for an oral carbapenem in cUTI, positions the company for potential significant value creation upon FDA filing and potential approval. The improved financial performance (reduced net loss, increased revenue) further supports a positive outlook, making it a strong buy for investors seeking exposure to a de-risked clinical-stage biopharmaceutical company with a clear path to market for its lead product.

Keywords

Spero Therapeutics, SPRO, Tebipenem HBr, cUTI, Complicated Urinary Tract Infection, Oral Carbapenem, Phase 3 Trial, PIVOT-PO, FDA Filing, GSK, Biopharmaceutical, Drug Development, Antibiotics, SPR720, NTM-PD, Clinical Stage, Financial Results, Biotech